Skip to main content

Thrive Capital Partners II, L.P.'s Form 4 filing

Oscar Health, Inc. (OSCR) · filed Sep 18, 2026

Accession no.
0001193125-26-395847
Filed
Sep 18, 2026, 8:21 PM ET
Trade date
Sep 18, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions and 5 derivative transactions. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Thrive Capital Partners II, L.P.CIK 0001527725Director, 10% Owner
Thrive Capital Partners III, L.P.CIK 0001556346Director, 10% Owner
Claremount TW, L.P.CIK 0001575445Director, 10% Owner
Thrive Capital Partners VII Growth, L.P.CIK 0001841736Director, 10% Owner
Claremount VII Associates, L.P.CIK 0001841808Director, 10% Owner
Thrive Partners III GP, LLCCIK 0001848080Director, 10% Owner
Thrive Partners II GP, LLCCIK 0001848082Director, 10% Owner
Thrive Partners VII GP, LLCCIK 0001877733Director, 10% Owner
Thrive Partners VII Growth GP, LLCCIK 0001877735Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 18, 2026Class A Common StockJOtherDisposed−6,268,097$0.00F1$00Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−75,520$0.00F1$00Indirect
Sep 18, 2026Class A Common StockJOtherAcquired+1,323,589$0.00F1$01,323,589Indirect
Sep 18, 2026Class A Common StockJOtherAcquired+4,855,810$0.00F1$04,855,810Indirect
Sep 18, 2026Class A Common StockJOtherAcquired+164,218$0.00F1$0164,218Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−1,323,589$0.00F4$00Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−4,855,810$0.00F4$00Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−164,218$0.00F4$00Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 18, 2026Class A Common StockJOtherDisposed−1,323,589$0.00F1$04,779,730Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−4,855,810$0.00F1$017,535,258Indirect
Sep 18, 2026Class A Common StockJOtherDisposed−164,218$0.00F1$0593,021Indirect
Sep 18, 2026Class A Common StockJOtherAcquired+6,268,097$0.00F1$06,268,097Indirect
Sep 18, 2026Class A Common StockJOtherAcquired+75,520$0.00F1$075,520Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On September 18, 2026, (i) Thrive Capital Partners II, L.P. ("Thrive II") transferred 1,307,831 and 15,758 shares of Class B Common Stock to Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and Claremount VII Associates, L.P. ("Claremount VII"), respectively, in exchange for 1,307,831 and 15,758 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively; (ii) Thrive Capital Partners III, L.P. ("Thrive III") transferred 4,798,003 and 57,807 shares of Class B Common Stock to Thrive VII Growth and Claremount VII, respectively, in exchange for 4,798,003 and 57,807 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively; (iii) Claremount TW, L.P. ("Claremount TW") transferred 162,263 and 1,955 shares of Class B Common Stock to Thrive VII Growth and Claremount VII, respectively, in exchange for 162,263 and 1,955 shares of Class A Common Stock held by Thrive VII Growth and Claremount VII, respectively.

Referenced by the price of 5 transactions in Table I and 5 transactions in Table II.

F4

On September 18, 2026, (i) Thrive II distributed to its limited partners and sole general partner, pro rata and without consideration, 1,323,589 shares of Class A Common Stock; (ii) Thrive III distributed to its limited partners and sole general partner, pro rata and without consideration, 4,855,810 shares of Class A Common Stock; and (iii) Claremount TW distributed to its limited partners and sole general partner, pro rata and without consideration, 164,218 shares of Class A Common Stock. Each of Thrive Partners II GP, LLC and Thrive Partners III GP, LLC, in turn, distributed to their members, pro rata and without consideration, the shares of Class A Common Stock received in the foregoing distributions. Such distributions were made in accordance with the exemptions afforded by Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Referenced by the price of 3 transactions in Table I.

Remarks

Joshua Kushner has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Kushner's representation, for purposes of Section 16 of the Exchange Act, each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Kushner has filed a separate Section 16 report disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.

Read the full filing on SEC EDGAR (opens in a new tab)